

Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Took December on	Value(a)	Deference Denne	000010122
Test Description	Value(s)	Reference Range	
COMPLETE BLOOD COUNT (CBC)			
Hemoglobin (Hb)	13.0	12.0 - 15.0	gm/dL
Erythrocyte (RBC) Count	4.41	3.8 - 4.8	mil/cu.mm
Packed Cell Volume (PCV)	38.1	36 - 46	%
Mean Cell Volume (MCV)	86.39	83 - 101	fL
Mean Cell Haemoglobin (MCH)	29.48	27 - 32	pg
Mean Corpuscular Hb Concn. (MCHC)	34.12	31.5 - 34.5	g/dL
Red Cell Distribution Width (RDW)	12.2	11.6 - 14.0	%
Total Leucocytes (WBC) Count	7300	4000-10000	cell/cu.mm
Neutrophils	67	40 - 80	%
Lymphocytes	25	20 - 40	%
Monocytes	7	2 - 10	%
Eosinophils	1	1 - 6	%
Basophils	0	1-2	%
Absolute Neutrophil Count	4891	2000 - 7000	/c.mm
Absolute Lymphocyte Count	1825	1000 - 3000	/c.mm
Absolute Monocyte Count	511	200 - 1000	/c.mm
Absolute Eosinophil Count	73	20 - 500	/c.mm
Absolute Basophils Count	0	20 - 100	/c.mm
Platelet Count	288	150 - 410	10^3/ul
Mean Platelet Volume (MPV)	10.1	7.2 - 11.7	fL
PCT	0.29	0.2 - 0.5	%
PDW	11.8	9.0 - 17.0	%
ESR	65.0	12.0 - 15.0	mm/hr

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

000816122

Test Description Value(s) Reference Range

URINE COMPLETE ANALYSIS,

Physical Examination

Quantity 15 - ml

Colour Pale Yellow Pale yellow/Yellow

Appearance Clear Clear

 Specific Gravity
 1.020
 1.005-1.025

 pH
 5.0
 5.0 - 8.0

 Deposit
 Present
 Absent

Chemical Examination

Protein Absent Absent Sugar Absent Absent **Ketones** Absent Absent **Bile Salt** Absent Absent **Bile Pigment** Absent Absent Urobilinogen Normal Normal

Microscopic Examination (/hpf)

Pus Cell Upto 5 1-2 1-2 **Epithelial Cells** Upto 5 **Red Blood Cells** Absent Absent Casts Absent Absent Crystals Absent Absent **Amorphous Deposit** Absent Absent **Yeast Cells** Absent Absent **Bacteria** Absent Absent Other findings Not seen Not seen







Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Reference Range

Test Description Value(s)

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
BLOOD GROUP & RH TYPING			
Blood Group (ABO typing)	"B"		
Method: Manual-Hemagglutination	Б		
RhD Factor (Rh Typing)	Positive		
Method: Manual hemagglutination	1 Oshive		

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

			000616122
Test Description	Value(s)	Reference Range	
Glycosylated HbA1c			
HbA1c (GLYCOSYLATED HEMOGLOBIN),	5.2		%
BLOOD			
Method: (HPLC, NGSP certified)			
Estimated Average Glucose :	102.54	-	mg/dL
Interpretation			
As per American Diabetes Association (ADA)			
Reference Group	HbA1c in %		
Non diabetic adults >=18 years	<5.7		
At risk (Prediabetes)	5.7 - 6.4		
Diagnosing Diabetes	>= 6.5		
	Age > 19 year	S	
	Goal of therap	y: < 7.0	
Therapeutic goals for glycemic control	Action sugges	ted: > 8.0	
	Age < 19 year	s	
	Goal of therap	y: <7.5	

Note:

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.
- Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant
 cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid
 conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

DRIIMA SARO IINI K MBBS DCP

Scan to Validate



Page 5 of 12



Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description

Value(s)

Reference Range

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID :

Test Description	Value(s)	Reference Range	
THYROID PROFILE TEST - TOTAL			
T3-Total	144.0	60 - 200	ng/dL
T4-Total	11.6	4.52 - 12	ug/dL
TSH-Ultrasensitive	4.63	0.32 - 5.5	uIU/mL
Method : CLIA		First Trimester: 0.1-2.5	
		Second Trimester: 0.2-3.0	
		Third trimester: 0.3-3.0	

Interpretation

TSH	Т3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness"
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy,Post radioiodine Hypothyroid phase of transient thyroiditis"
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease). Multinodular goitre, Toxic nodule •Transient thyroiditis: Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain's), Gestational thyrotoxicosis with hyperemesis gravidarum"
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
LIPID PROFILE			
Cholesterol-Total Method : Spectrophotometry	144.0	Desirable level < 200 Borderline High 200-239 High >or = 240	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	62.0	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method : Serum, Direct measure-PEG	50.0	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method : Enzymatic selective protection	81.60	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method : Serum, Enzymatic	12.40	6 - 38	mg/dL
CHOL/HDL Ratio Method : Serum, Enzymatic	2.88	3.5 - 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic Note:	1.63	2.5 - 3.5	
8-10 hours fasting sample is required.			

END OF REPORT

A SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

			000010122
Test Description	Value(s)	Reference Range	
RENAL PROFILE			
Urea	18.0	15-36	mg/dL
Method : Uricase			
Blood Urea Nitrogen-BUN	8.40	7 - 17	mg/dL
Method : Serum, Urease			
Creatinine	0.61	0.52-1.25	mg/dL
Method : Serum, Jaffe			
Uric Acid	5.4	2.5 - 6.2	mg/dL
Method : Serum, Uricase			
Remark:			
In blood, Urea is usually reported as BU	JN and expressed in mg/dl.	BUN mass units can be convert	ed to urea mass units by
multiplying by 2.14.			

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time: Jun 10, 2022, 09:29 a.m. **Reporting Time**: Jun 10, 2022, 01:56 p.m.

Sample ID:

000816122

Test Description	Value(s)	Reference Range	
LIVER FUNCTION TEST			
Total Protein	8.1	6.3-8.2	g/dL
Method : Serum, Biuret, reagent blank end point			3 ·
Albumin	4.0	3.5-5.0	g/dL
Method : Serum, Bromocresol green			•
Globulin	4.10	1.8 - 3.6	g/dL
Method : Serum, EIA			
A/G Ratio	0.98	1.2 - 2.2	
Method : Serum, EIA			
Bilirubin - Total	1.0	0.3-1.2	mg/dL
Method : Serum, Jendrassik Grof			
Bilirubin - Direct	0.2	< 0.2	mg/dL
Method : Serum, Diazotization			
Bilirubin - Indirect	0.8	0.1 - 1.0	mg/dL
Method : Serum, Calculated			
SGOT	21.0	14-36	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	17.0	9-52	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase	132.0	30 - 120	U/L
Method : PNPP-AMP Buffer/Kinetic			
GGT-Gamma Glutamyl Transpeptidae Method : Serum, G-glutamyl-carboxy-nitoanilide	26.0	< 38	U/L

END OF REPORT







Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral : MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (F)			
Glucose fasting Method : GOD-POD	107.0	Normal: 70 - 120	mg/dL

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. INDHUMATHI V

Age / Gender: 30 years / Female

Patient ID: 96633

Referral: MediWheel

Collection Time : Jun 10, 2022, 09:29 a.m. **Reporting Time :** Jun 10, 2022, 01:56 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (PP) Blood Glucose-Post Prandial	119.0	80- 140	mg/dL
Method : GOD-POD			J

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

